Drug Profile
Topiramate extended-release - Supernus Pharmaceuticals
Alternative Names: SPN-538; Topiramate controlled-release - Supernus Pharmaceuticals; TPM XR; Trokendi XR; TrokesaLatest Information Update: 03 Dec 2021
Price :
$50
*
At a glance
- Originator Supernus Pharmaceuticals
- Class Antiepileptic drugs; Antimigraines; Dioxolanes; Hexoses; Ketoses; Neuroprotectants; Obesity therapies; Pyrans; Small molecules; Sulfonic acids
- Mechanism of Action AMPA receptor antagonists; Carbonic anhydrase inhibitors; GABA A receptor agonists; Kainic acid receptor antagonists; Sodium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Marketed Epilepsy; Migraine
Most Recent Events
- 31 Dec 2020 Supernus enters into a collaboration agreement with Stendhal Mexico for commercialisation of oxcarbazepine extended release outside of the US, prior to December 2020
- 31 Dec 2020 Supernus has patent protection for topiramate extended-release in Mexico, Australia, Japan, Canada and Europe, prior to December 2020
- 31 Dec 2020 Supernus has patent protection for topiramate extended-release in USA, prior to December 2020